Voyager Therapeutics Files 2025 Proxy Statement
Ticker: VYGR · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1640266
Sentiment: neutral
Topics: proxy-statement, executive-compensation, governance
TL;DR
Voyager's proxy statement is out, detailing exec pay and equity awards for 2024.
AI Summary
Voyager Therapeutics, Inc. filed its DEF 14A on April 23, 2025, for the fiscal year ending December 31, 2025. The filing details executive compensation, including equity awards granted to individuals like Alfred Sandrock. Specific details on the fair value of these awards, vesting dates, and changes in value are provided for the fiscal year 2024.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance, enabling informed voting decisions on proposals presented at the annual meeting.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details within can reveal significant information about executive compensation, potential shareholder disputes, or changes in corporate strategy that could impact stock value.
Key Numbers
- 20250423 — Filing Date (Date the DEF 14A was filed with the SEC)
- 20250603 — Period of Report (The fiscal period the report pertains to)
- 1231 — Fiscal Year End (Indicates the end of the company's fiscal year)
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Filer of the DEF 14A
- Alfred Sandrock (person) — Executive whose compensation is detailed
- Michael Higgins (person) — Member mentioned in relation to compensation data
- 75 Hayden Avenue, Lexington, MA 02421 (address) — Company's business and mailing address
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors and executive compensation.
Who is Alfred Sandrock and what is his role at Voyager Therapeutics?
Alfred Sandrock is identified as a member, and his compensation details, including equity awards, are provided for the fiscal years 2022, 2023, and 2024.
What specific compensation data is provided for the fiscal year 2024?
The filing provides data for the fiscal year 2024 concerning the year-end fair value of equity awards granted, outstanding and unvested awards, vesting dates, and changes in fair value for individuals like Alfred Sandrock.
What is the company's standard industrial classification?
Voyager Therapeutics, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with the SIC code [2836].
Where is Voyager Therapeutics, Inc. headquartered?
Voyager Therapeutics, Inc. is located at 75 Hayden Avenue, Lexington, MA 02421.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 by Alfred Sandrock regarding Voyager Therapeutics, Inc. (VYGR).